The Prognostic Significance of the TEAD4 in Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25. doi:10.1007/s00261-017-1209-1
   PubMed Web of Science ®Google Scholar
• Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284–293. doi:10.1016/j.jhep.2018.10.008
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhang J, Ni X. Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus. Oncol Lett. 2020;20(4):101. doi:10.3892/ol.2020.11962
   PubMed Web of Science ®Google Scholar
• Li JJ, Liang Q, Sun GC. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med. 2021;19(6):469–477. doi:10.1016/j.joim.2021.08.004
   PubMed Web of Science ®Google Scholar
• Ji Y, Yin Y, Zhang W. Integrated bioinformatic analysis identifies networks and promising biomarkers for hepatitis B virus-related hepatocellular carcinoma. Int J Genomics. 2020;2020:2061024. doi:10.1155/2020/2061024
   PubMed Web of Science ®Google Scholar
• Liu T, Wu H, Qi J, et al. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. Cancer Med. 2020;9(20):7440–7452.
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Cao X, Shao Y, Meng P, et al. Nascent proteome and glycoproteome reveal the inhibition role of ALG1 in hepatocellular carcinoma cell migration. Phenomics. 2022;2(4):230–241. doi:10.1007/s43657-022-00050-5
   PubMedGoogle Scholar
• Pobbati AV, Kumar R, Rubin BP, et al. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci. 2023;48(5):450–462. doi:10.1016/j.tibs.2022.12.005
   PubMed Web of Science ®Google Scholar
• Fan M, Lu W, Che J, et al. Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling. eLife. 2022;11:e78810. doi:10.7554/eLife.78810
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19(7):480–494. doi:10.1038/s41573-020-0070-z
   PubMed Web of Science ®Google Scholar
• Tomikawa J, Takada S, Okamura K, et al. Exploring trophoblast-specific Tead4 enhancers through chromatin conformation capture assays followed by functional screening. Nucleic Acids Res. 2020;48(1):278–289. doi:10.1093/nar/gkz1034
   PubMed Web of Science ®Google Scholar
• Tsinias G, Nikou S, Mastronikolis N, et al. Expression and prognostic significance of YAP, TAZ, TEAD4 and p73 in human laryngeal cancer. Histol Histopathol. 2020;2020:18228.
   Google Scholar
• Chi M, Liu J, Mei C, et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41(1):175. doi:10.1186/s13046-022-02377-3
   PubMed Web of Science ®Google Scholar
• Im JY, Kim DM, Park H, et al. VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118892. doi:10.1016/j.bbamcr.2020.118892
   PubMed Web of Science ®Google Scholar
• Tschaharganeh DF, Chen X, Latzko P, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530–1542 e1512. doi:10.1053/j.gastro.2013.02.009
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu P, Tao J, et al. TEA domain transcription factor 4 is the major mediator of yes-associated protein oncogenic activity in mouse and human hepatoblastoma. Am J Pathol. 2019;189(5):1077–1090. doi:10.1016/j.ajpath.2019.01.016
   PubMed Web of Science ®Google Scholar
• Weiler S. YAP induziert chromosomale Instabilität in Leberkrebspatienten [YAP induces chromosomal instability in liver cancer patients]. Pathologe. 2018;39(Suppl 2):185–188. German. doi:10.1007/s00292-018-0494-y
   PubMedGoogle Scholar
• Jiao S, Guan J, Chen M, et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J Exp Med. 2018;215(2):699–718. doi:10.1084/jem.20171116
   PubMed Web of Science ®Google Scholar
• Li SK, Tang HC, Man-Hon Leung M, et al. Centrosomal protein TAX1BP2 inhibits centrosome-microtubules aberrations induced by hepatitis B virus X oncoprotein. Cancer Lett. 2020;492:147–161. doi:10.1016/j.canlet.2020.08.005
   PubMed Web of Science ®Google Scholar
• Cai WY, Lin LY, Hao H, et al. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice. Hepatology. 2017;65(4):1206–1221. doi:10.1002/hep.28911
   PubMed Web of Science ®Google Scholar
• Feng X, Lu T, Li J, et al. The tumor suppressor interferon regulatory factor 2 binding protein 2 regulates hippo pathway in liver cancer by a feedback loop in mice. Hepatology. 2020;71(6):1988–2004. doi:10.1002/hep.30961
   PubMed Web of Science ®Google Scholar
• Shi Z, He F, Chen M, et al. DNA-binding mechanism of the hippo pathway transcription factor TEAD4. Oncogene. 2017;36(30):4362–4369. doi:10.1038/onc.2017.24
   PubMed Web of Science ®Google Scholar
• White SM, Murakami S, Yi C. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity. Oncogene. 2019;38(16):2899–2909. doi:10.1038/s41388-018-0649-6
   PubMed Web of Science ®Google Scholar
• Yang W, Yang S, Zhang F, et al. Influence of the hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med. 2020;8(6):399. doi:10.21037/atm.2020.02.11
   PubMed Web of Science ®Google Scholar
• Guo X, Zhao Y, Yan H, et al. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017;31(3):247–259. doi:10.1101/gad.294348.116
   PubMed Web of Science ®Google Scholar